Does the media favor GMAB or DYN?

In the previous week, Dyne Therapeutics had 23 more articles in the media than Genmab A/S. MarketBeat recorded 24 mentions for Dyne Therapeutics and 1 mentions for Genmab A/S. Dyne Therapeutics' average media sentiment score of 0.23 beat Genmab A/S's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer DYN or BBIO?

In the previous week, Dyne Therapeutics had 16 more articles in the media than BridgeBio Pharma. MarketBeat recorded 24 mentions for Dyne Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.41 beat Dyne Therapeutics' score of 0.23 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral BridgeBio Pharma 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ASND or DYN?

In the previous week, Dyne Therapeutics had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Dyne Therapeutics and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Dyne Therapeutics' score of 0.23 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 3 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is EXEL or DYN more profitable?

Exelixis has a net margin of 35.33% compared to Dyne Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Dyne Therapeutics N/A -64.30% -50.33%

Does the media prefer EXEL or DYN?

In the previous week, Dyne Therapeutics had 11 more articles in the media than Exelixis. MarketBeat recorded 24 mentions for Dyne Therapeutics and 13 mentions for Exelixis. Exelixis' average media sentiment score of 1.06 beat Dyne Therapeutics' score of 0.23 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 8 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer BMRN or DYN?

In the previous week, BioMarin Pharmaceutical had 11 more articles in the media than Dyne Therapeutics. MarketBeat recorded 35 mentions for BioMarin Pharmaceutical and 24 mentions for Dyne Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.74 beat Dyne Therapeutics' score of 0.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioMarin Pharmaceutical 13 Very Positive mention(s) 6 Positive mention(s) 9 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Dyne Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Dyne Therapeutics (DYN) Competitors

$26.10 +0.12 (+0.46%)

As of 08/21/2026 04:00 PM Eastern

Compare

DYN vs. GMAB, BBIO, ASND, EXEL, and BMRN

Should you buy Dyne Therapeutics stock or one of its competitors? Dyne Therapeutics's main competitors and comparable companies include Genmab A/S (GMAB), BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and BioMarin Pharmaceutical (BMRN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Dyne Therapeutics compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, profitability, dividends, institutional ownership, earnings, media sentiment and valuation.

Genmab A/S has a net margin of 19.08% compared to Dyne Therapeutics' net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 23 more articles in the media than Genmab A/S. MarketBeat recorded 24 mentions for Dyne Therapeutics and 1 mentions for Genmab A/S. Dyne Therapeutics' average media sentiment score of 0.23 beat Genmab A/S's score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genmab A/S currently has a consensus price target of $39.50, indicating a potential upside of 18.09%. Dyne Therapeutics has a consensus price target of $34.42, indicating a potential upside of 31.86%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Genmab A/S has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.61	$963M	$1.27	26.34
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Summary

Dyne Therapeutics beats Genmab A/S on 9 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to BridgeBio Pharma?

Dyne Therapeutics (NASDAQ:DYN) and BridgeBio Pharma (NASDAQ:BBIO) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, valuation, profitability, media sentiment, risk, dividends, earnings and institutional ownership.

Dyne Therapeutics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -97.03%. BridgeBio Pharma's return on equity of 0.00% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
BridgeBio Pharma	-97.03%	N/A	-61.19%

In the previous week, Dyne Therapeutics had 16 more articles in the media than BridgeBio Pharma. MarketBeat recorded 24 mentions for Dyne Therapeutics and 8 mentions for BridgeBio Pharma. BridgeBio Pharma's average media sentiment score of 0.41 beat Dyne Therapeutics' score of 0.23 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
BridgeBio Pharma	4 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Dyne Therapeutics has higher earnings, but lower revenue than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A
BridgeBio Pharma	$502.08M	31.73	-$724.93M	-$3.57	N/A

Dyne Therapeutics has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market. Comparatively, BridgeBio Pharma has a beta of 0.96, indicating that its share price is 4% less volatile than the broader market.

96.7% of Dyne Therapeutics shares are held by institutional investors. Comparatively, 99.9% of BridgeBio Pharma shares are held by institutional investors. 9.5% of Dyne Therapeutics shares are held by insiders. Comparatively, 14.2% of BridgeBio Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dyne Therapeutics presently has a consensus target price of $34.42, indicating a potential upside of 31.86%. BridgeBio Pharma has a consensus target price of $100.79, indicating a potential upside of 23.67%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Dyne Therapeutics is more favorable than BridgeBio Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	20 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Dyne Therapeutics beats BridgeBio Pharma on 10 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, dividends, valuation, earnings, media sentiment, institutional ownership and profitability.

96.7% of Dyne Therapeutics shares are held by institutional investors. 40.0% of Ascendis Pharma A/S shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Ascendis Pharma A/S has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	19.40	-$258M	$12.89	19.65
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Ascendis Pharma A/S has a net margin of 70.99% compared to Dyne Therapeutics' net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
Dyne Therapeutics	N/A	-64.30%	-50.33%

In the previous week, Dyne Therapeutics had 14 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 24 mentions for Dyne Therapeutics and 10 mentions for Ascendis Pharma A/S. Ascendis Pharma A/S's average media sentiment score of 0.71 beat Dyne Therapeutics' score of 0.23 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	3 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S currently has a consensus price target of $300.33, indicating a potential upside of 18.57%. Dyne Therapeutics has a consensus price target of $34.42, indicating a potential upside of 31.86%. Given Dyne Therapeutics' higher possible upside, analysts plainly believe Dyne Therapeutics is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.05
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Ascendis Pharma A/S has a beta of 0.39, indicating that its stock price is 61% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Summary

Ascendis Pharma A/S beats Dyne Therapeutics on 11 of the 15 factors compared between the two stocks.

How does Dyne Therapeutics compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, media sentiment, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Exelixis presently has a consensus target price of $50.07, indicating a potential downside of 7.42%. Dyne Therapeutics has a consensus target price of $34.42, indicating a potential upside of 31.86%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Dyne Therapeutics is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	2 Sell rating(s)	11 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.30
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Exelixis has a net margin of 35.33% compared to Dyne Therapeutics' net margin of 0.00%. Exelixis' return on equity of 42.17% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Dyne Therapeutics	N/A	-64.30%	-50.33%

Exelixis has a beta of 0.44, indicating that its stock price is 56% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

In the previous week, Dyne Therapeutics had 11 more articles in the media than Exelixis. MarketBeat recorded 24 mentions for Dyne Therapeutics and 13 mentions for Exelixis. Exelixis' average media sentiment score of 1.06 beat Dyne Therapeutics' score of 0.23 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	8 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	5.78	$782.57M	$3.18	17.01
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

Summary

Exelixis and Dyne Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

BioMarin Pharmaceutical (NASDAQ:BMRN) and Dyne Therapeutics (NASDAQ:DYN) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, valuation, institutional ownership, profitability, risk and analyst recommendations.

BioMarin Pharmaceutical has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioMarin Pharmaceutical	$3.22B	4.01	$348.90M	$0.37	180.27
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.33	N/A

BioMarin Pharmaceutical has a net margin of 2.14% compared to Dyne Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 5.32% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioMarin Pharmaceutical	2.14%	5.32%	3.69%
Dyne Therapeutics	N/A	-64.30%	-50.33%

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 0.7% of BioMarin Pharmaceutical shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

BioMarin Pharmaceutical has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.07, suggesting that its share price is 7% more volatile than the broader market.

In the previous week, BioMarin Pharmaceutical had 11 more articles in the media than Dyne Therapeutics. MarketBeat recorded 35 mentions for BioMarin Pharmaceutical and 24 mentions for Dyne Therapeutics. BioMarin Pharmaceutical's average media sentiment score of 0.74 beat Dyne Therapeutics' score of 0.23 indicating that BioMarin Pharmaceutical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioMarin Pharmaceutical	13 Very Positive mention(s)	6 Positive mention(s)	9 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyne Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

BioMarin Pharmaceutical currently has a consensus price target of $88.83, indicating a potential upside of 33.17%. Dyne Therapeutics has a consensus price target of $34.42, indicating a potential upside of 31.86%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioMarin Pharmaceutical	1 Sell rating(s)	6 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.75
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	2.87

Summary

BioMarin Pharmaceutical beats Dyne Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Dyne Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYN vs. The Competition

Export

Metric	Dyne Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.85B	$3.96B	$7.27B	$12.76B
Dividend Yield	N/A	3.64%	2.54%	11.09%
P/E Ratio	-7.84	11.52	270.69	24.20
Price / Sales	N/A	1,409.66	639.89	109.39
Price / Cash	N/A	103.29	76.89	53.23
Price / Book	6.94	17.90	13.43	6.37
Net Income	-$446.21M	-$12.50M	$3.46B	$347.74M
7 Day Performance	1.56%	3.23%	2.15%	0.06%
1 Month Performance	12.45%	7.72%	6.18%	2.86%
1 Year Performance	107.47%	55.10%	24.96%	17.13%

Dyne Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYN Dyne Therapeutics	3.5472 of 5 stars	$26.10 +0.5%	$34.42 +31.9%	+113.6%	$4.85B	N/A	N/A	100	Analyst Revision
GMAB Genmab A/S	3.4566 of 5 stars	$30.87 -1.2%	$39.50 +28.0%	+37.0%	$19.49B	$3.72B	24.31	3,029
BBIO BridgeBio Pharma	3.2394 of 5 stars	$84.67 +0.2%	$97.33 +15.0%	+62.3%	$16.51B	$502.08M	N/A	400	Insider Trade
ASND Ascendis Pharma A/S	4.5677 of 5 stars	$255.62 +0.1%	$296.12 +15.8%	+31.4%	$15.93B	$814.57M	29.48	1,189	Earnings Report Analyst Forecast Insider Trade
EXEL Exelixis	3.3544 of 5 stars	$52.96 -2.1%	$49.79 -6.0%	+39.7%	$13.59B	$2.32B	16.65	1,077	Positive News Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYN) was last updated on 8/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyne Therapeutics (DYN) Competitors

DYN vs. GMAB, BBIO, ASND, EXEL, and BMRN

How does Dyne Therapeutics compare to Genmab A/S?

Summary

How does Dyne Therapeutics compare to BridgeBio Pharma?

Summary

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Summary

How does Dyne Therapeutics compare to Exelixis?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyne Therapeutics (DYN) Competitors

DYN vs. GMAB, BBIO, ASND, EXEL, and BMRN

How does Dyne Therapeutics compare to Genmab A/S?

Is GMAB or DYN more profitable?

Does the media favor GMAB or DYN?

Do analysts prefer GMAB or DYN?

Which has more risk and volatility, GMAB or DYN?

Do insiders & institutionals believe in GMAB or DYN?

Which has stronger earnings and valuation, GMAB or DYN?

Summary

How does Dyne Therapeutics compare to BridgeBio Pharma?

Is DYN or BBIO more profitable?

Does the media prefer DYN or BBIO?

Which has stronger earnings & valuation, DYN or BBIO?

Which has more volatility & risk, DYN or BBIO?

Do institutionals & insiders hold more shares of DYN or BBIO?

Do analysts rate DYN or BBIO?

Summary

How does Dyne Therapeutics compare to Ascendis Pharma A/S?

Do institutionals and insiders hold more shares of ASND or DYN?

Which has better valuation & earnings, ASND or DYN?

Is ASND or DYN more profitable?

Does the media prefer ASND or DYN?

Do analysts rate ASND or DYN?

Which has more risk and volatility, ASND or DYN?

Summary

How does Dyne Therapeutics compare to Exelixis?

Do insiders and institutionals hold more shares of EXEL or DYN?

Do analysts rate EXEL or DYN?

Is EXEL or DYN more profitable?

Which has more risk & volatility, EXEL or DYN?

Does the media prefer EXEL or DYN?

Which has higher earnings and valuation, EXEL or DYN?

Summary

How does Dyne Therapeutics compare to BioMarin Pharmaceutical?

Which has stronger valuation and earnings, BMRN or DYN?

Is BMRN or DYN more profitable?

Do insiders & institutionals hold more shares of BMRN or DYN?

Which has more volatility & risk, BMRN or DYN?

Does the media prefer BMRN or DYN?

Do analysts rate BMRN or DYN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYN vs. The Competition

Dyne Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools